AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28916992
Drug: Daily vitamin
RxNorm normalized name: Daily Vitamin Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily vitamin D3 (400 IU)
Trial: 28916992
Drug: Daily vitamin
RxNorm normalized name: Daily Vitamin Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily vitamin D3 (1000 IU)
Trial: 17493496
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of epinephrine
Trial: 15505276
Drug: TAM 30
RxNorm normalized name: Pentam 300
DrugBank: Pentamidine (DB00738)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TAM 30 mg/d for 3 years
Trial: 15505276
Drug: EPI 30
RxNorm normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPI 30 mg on days 1, 8, and 15 every 28 days for six cycles plus TAM 30 mg/d for 3 years
Trial: 29792232
Drug: CI-guided goal-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CI-guided goal-directed hemodynamic therapy (GDHT)
Trial: 15735202
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin treatment for 10 days (T(2)D+); plasma glucose 5.5 ± 0.2 mmol/l
Trial: 15735202
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of all antidiabetic medications for 2 weeks (T(2)D-); plasma glucose 12.6 ± 1.0 mmol/l
Trial: 11895895
Drug: BCL-2 antisense
RxNorm normalized name: Exon 53 specific antisense morpholino oligonucleotide
DrugBank: Viltolarsen (DB15005)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: BCL-2 antisense oligonucleotide (G3139) at 6.9 mg/kg/day
Trial: 10332543
Drug: Intravenous salmon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous salmon calcitonin 200 IU
Trial: 9102059
Drug: Intranasal calcitonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal calcitonin
Trial: 10332543
Drug: Long-term studies
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term studies using intranasal calcitonin
Trial: 7676060
Drug: Parenteral spread
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parenteral spread of infections agents
Trial: 2202902
Drug: Isotretinoin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotretinoin (50 to 100 mg per square meter of body-surface area per day)
Trial: 6117260
Drug: 650 mg
RxNorm normalized name: bran 650 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 650 mg aspirin administered 12 hours before operation
Trial: 30959146
Drug: Adjusted medication
RxNorm normalized name: DEPEND ADJUSTABLE,MAXIMUM SM/MED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted medication protocol
Trial: 30959146
Drug: Fixed medication
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed medication protocol
Trial: 28381416
Drug: Lenalidomide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide (25 mg/day for 21 days of a 28-day cycle)
Trial: 16875928
Drug: Fosinopril (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril (low dosage)
Trial: 16875928
Drug: Fosinopril (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril (high dosage)
Trial: 12629054
Drug: Fluconazole (Fluzole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (Fluzole 100 mg/day) starting from the sixth irradiation session throughout the treatment
Trial: 12629054
Drug: Fluconazole (Fluzole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (Fluzole 100 mg/day)
Trial: 9311220
Drug: Intravenous neostigmine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous neostigmine (2 ml, 1 mg)
Trial: 9311220
Drug: Atropine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (1 ml, 0.5 mg) and neostigmine (2 ml, 1 mg)
Trial: 23011423
Drug: Microcurrent reflexology
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcurrent reflexology sessions and cortexin treatment (10 mg, 10 injections)
Trial: 23011423
Drug: Reflexology treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reflexology treatments only
Trial: 15737667
Drug: Tryptophan-free mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tryptophan-free mixture (31.2 g of amino acids)
Trial: 15737667
Drug: Control mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control mixture (33.2 g of amino acids)
Trial: 14523211
Drug: Chlorhexidine (4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine (4% detergent water solution)
Trial: 4008115
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg theophylline
Trial: 2071262
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg theophylline followed by 400 mg rufloxacin after 30 min
Trial: 2071262
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg caffeine followed by 400 mg rufloxacin after 30 min
Trial: 6357692
Drug: Calcium antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonist (Bay K 9320) 20 mg, three times daily for three weeks
Trial: 6357692
Drug: Calcium antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonist (Bay K 9320)
Trial: 31995024
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg for three months
Trial: 31995024
Drug: Metformin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin monotherapy subgroup with Esomeprazole
Trial: 19669019
Drug: Supplementary oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplementary oxygen administration
Trial: 17438407
Drug: Sarpogrelate hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Sarpogrelate (DB12163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarpogrelate hydrochloride 100 mg 3 times per day orally for 12 weeks
Trial: 11181869
Drug: GKI infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GKI infusion (500 ml 10% glucose, 20 mmol potassium chloride, 16 units of insulin)
Trial: 11181869
Drug: Control therapy
RxNorm normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control therapy with 154 mmol/l (0.9%) saline at 100 ml/h for 24 hours
Trial: 10211539
Drug: Sparfloxacin 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparfloxacin 400 mg loading dose on day 1, followed by 200 mg daily for 9 days
Trial: 2620532
Drug: Cervagem (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervagem (1 mg vaginal suppository for 4 hours)
Trial: 29605624
Drug: Tiotropium-olodaterol 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium-olodaterol 5 μg-5 μg once daily
Trial: 29605624
Drug: Tiotropium 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 5 μg once daily
Trial: 22610452
Drug: 7% hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7% hypertonic saline, nebulized twice daily for 48 weeks
Trial: 22610452
Drug: 0.9% isotonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% isotonic saline, nebulized twice daily for 48 weeks
Trial: 20415801
Drug: Xylitol rinse
RxNorm normalized name: Xylitol
DrugBank: Xylitol (DB11195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xylitol rinse (20 mL of an aqueous solution of xylitol twice daily for 60 seconds, dose: 4.4 g/day)
Trial: 20415801
Drug: Xylitol chewing
RxNorm normalized name: xylitol Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylitol chewing gum (two xylitol gum pellets for at least 5 minutes three times daily, dose: 4.3g/day)
Trial: 18710748
Drug: Gonadotropin-releasing hormone
RxNorm normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gonadotropin-releasing hormone agonist therapy (2, 6-month cycles)
Trial: 18710748
Drug: Prior local
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior local radiation therapy
Trial: 15933273
Drug: Activities of
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activities of daily living (ADLs) dependence
Trial: 11398305
Drug: Dihydroergotamine (DHE)
DrugBank: Dihydroergotamine (DB00320)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dihydroergotamine (DHE) nasal spray 1 mg
Trial: 11398305
Drug: Dihydroergotamine (DHE)
DrugBank: Dihydroergotamine (DB00320)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dihydroergotamine (DHE) nasal spray 0.5 mg
Trial: 11398305
Drug: Dihydroergotamine (DHE)
DrugBank: Dihydroergotamine (DB00320)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dihydroergotamine (DHE) nasal spray (both doses)
Trial: 11398305
Drug: Dihydroergotamine (DHE)
DrugBank: Dihydroergotamine (DB00320)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dihydroergotamine (DHE) nasal spray
Trial: 2464912
Drug: Fluvoxamine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (200 mg per day for 4 weeks)
Trial: 2186673
Drug: Intranasal budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intranasal budesonide 200 micrograms bid
Trial: 31659612
Drug: Serum AFP
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum AFP ≥ 100 ng/ml
Trial: 28496190
Drug: Combination budesonide/formoterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination budesonide/formoterol inhaler (single maintenance and reliever therapy)
Trial: 28496190
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose budesonide/formoterol with salbutamol as reliever (Standard regimen)
Trial: 9797591
Drug: Ibuprofen syrup
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen syrup (intervention group)
Trial: 8054915
Drug: IFN‐alpha 2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN‐alpha 2a at a dose of 1 x 10(6) units/day sc for 28 days with CYA
Trial: 8054915
Drug: IFN‐alpha 2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN‐alpha 2a at a dose of 3 x 10(6) units/day sc for 28 days with CYA
Trial: 19515371
Drug: Drug conservation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug conservation (DC)
Trial: 27027634
Drug: 6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg grapiprant suspension
Trial: 27027634
Drug: 50 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/kg grapiprant suspension
Trial: 27027634
Drug: 6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg grapiprant tablet
Trial: 27027634
Drug: 50 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/kg grapiprant tablet
Trial: 16106334
Drug: Cognitive-behavioral group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral group therapy (CBT) for 8 sessions over 8 weeks
Trial: 11828293
Drug: Vancomycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (1 g every 12 hours)
Trial: 11828293
Drug: Cefazolin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (1 g every 8 hours)
Trial: 9895384
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose amino acids (LDA)
Trial: 9895384
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose amino acids (HDA)
Trial: 153863
Drug: 75 mg/day
RxNorm normalized name: Lyllana 0.075 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg/day of Ro 10‐9359
Trial: 153863
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg twice every week of Ro 10‐9359
Trial: 31553835
Drug: Quintupling the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quintupling the dose of fluticasone (to 250 μg twice a day)
Trial: 31553835
Drug: Doubling the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doubling the fluticasone (to 100 μg twice a day) and adding salmeterol (50 μg twice a day)
Trial: 31553835
Drug: Salmeterol (low-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol (low-dose fluticasone)
Trial: 31553835
Drug: Salmeterol (medium-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol (medium-dose fluticasone)
Trial: 26945216
Drug: Interferential Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferential Therapy (IFT) with standard care
Trial: 20697200
Drug: Hib(2.5 µg)‐MenC(5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hib(2.5 µg)‐MenC(5 µg)‐MenY(5 µg)‐TT co-administered with DTPa‐HBV‐IPV
Trial: 20697200
Drug: Hib(5 µg)‐MenC(10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hib(5 µg)‐MenC(10 µg)‐MenY(10 µg)‐TT co-administered with DTPa‐HBV‐IPV
Trial: 20697200
Drug: Hib(5 µg)‐MenC(5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hib(5 µg)‐MenC(5 µg)‐MenY(5 µg)‐TT co-administered with DTPa‐HBV‐IPV
Trial: 20697200
Drug: Hib(5 µg)‐MenC(5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hib(5 µg)‐MenC(5 µg)‐TT co-administered with DTPa‐HBV‐IPV
Trial: 20697200
Drug: Licensed conjugate
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Licensed conjugate MenC‐CRM197 vaccine co-administered with DTPa‐HBV‐IPV/Hib
Trial: 20697200
Drug: HibMenCY and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HibMenCY and HibMenC conjugate vaccines
Trial: 1525095
Drug: Active policy
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active policy (immediate oxytocin infusion)
Trial: 3839262
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy with periodic BCVP reinduction
Trial: 31155161
Drug: MOSAIC treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOSAIC treatment (two 60-minute home-based sessions and two 20-minute booster telephone calls incorporating behavior-change techniques)
Trial: 27103215
Drug: Dilemma-focused therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilemma-focused therapy (DFT)
Trial: 24662855
Drug: TEG-guided dosing
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEG-guided dosing (50 mg twice a day)
Trial: 24662855
Drug: Standard dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosing (30 mg twice a day)
Trial: 20962021
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus lifestyle program of weight management
Trial: 19564296
Drug: Electronic health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic health record-based clinical alerts for influenza vaccine at intervention sites
Trial: 17309130
Drug: Fasting insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fasting insulin levels in SLE patients
Trial: 7727578
Drug: No antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiretroviral treatment (No Rx)
Trial: 2035339
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of medicamentous therapy and percutaneous drainage
Trial: 28704587
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate 50, 125, 300 or 600 mg weekly
Trial: 28704587
Drug: Dutasteride 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutasteride 2.5 mg daily
Trial: 17968938
Drug: Quinapril 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril 80 mg/day
Trial: 19121433
Drug: Drug-eluting stents
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting stents (DESs)
Trial: 11802510
Drug: Sucralfate 1
RxNorm normalized name: sucralfate 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate 1 g t.d.s. for 4 weeks (SAC group; n = 60)
Trial: 11802510
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg b.d. for the first 7 days and 40 mg o.d. for the next 3 weeks (PAC group; n = 60)
Trial: 7449642
Drug: Immunosuppressive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive treatment with prednisolone and azathioprine
Trial: 7449642
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no immunosuppressive treatment)
Trial: 27588568
Drug: Liposomal iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal iron 28 mg (LI28)
Trial: 27588568
Drug: Liposomal iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal iron 14 mg (LI14)
Trial: 27588568
Drug: Ferrous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferrous iron 30 mg (FI)
Trial: 24106757
Drug: 0.05% S.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% S. flavescens extract cream
Trial: 18761603
Drug: Peg‐IFN alpha‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peg‐IFN alpha‐2a monotherapy (n = 59)
Trial: 18761603
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (n = 61)
Trial: 18761603
Drug: Peg‐IFN alpha‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peg‐IFN alpha‐2a monotherapy with low viraemia (≤300,000 IU/mL)
Trial: 18761603
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with low viraemia (≤300,000 IU/mL)
Trial: 18761603
Drug: Peg‐IFN alpha‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peg‐IFN alpha‐2a monotherapy with intermediate viraemia (>300,000 IU/mL and ≤700,000 IU/mL)
Trial: 18761603
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with intermediate viraemia (>300,000 IU/mL and ≤700,000 IU/mL)
Trial: 18761603
Drug: Peg‐IFN alpha‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peg‐IFN alpha‐2a monotherapy with high viraemia (>700,000 IU/mL)
Trial: 18761603
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with high viraemia (>700,000 IU/mL)
Trial: 11468498
Drug: Collaborative care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative care program supervised by a psychiatrist and a primary care expert, providing intervention services for 12 months using antidepressant medications and Problem Solving Treatment in Primary Care.
Trial: 9503770
Drug: Topical anesthetics
RxNorm normalized name: topical anesthetics (obsolete)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthetics (various types including vapocoolants, needleless injection systems, iontophoresis, EMLA Cream)
Trial: 8061739
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration therapy (enteral administration of a balanced glucose-electrolyte solution)
Trial: 8061739
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration solutions with additional benefits
Trial: 3361903
Drug: Alcohol (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (dose not specified)
Trial: 28186711
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose statin exposure (EM 1)
Trial: 28186711
Drug: Cumulative standardized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative standardized statin dose at index date (EM 2)
Trial: 28186711
Drug: Cumulative standardized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative standardized statin dose in the 180 days prior to index date (EM 3)
Trial: 21239518
Drug: Vildagliptin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin (100 mg once daily for 13 days)
Trial: 8741955
Drug: 21 mg/day
RxNorm normalized name: nicotine 21 MG/Day 24HR Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 mg/day nicotine skin patch for smokers